Paul is a Scientist at Caribou Biosciences in the Technology Development group. He received his B.S. from the University of California, Davis in Biochemistry and Molecular Biology. As an early employee at Caribou, his initial research centered on identifying the key structural features of the Type II guide RNAs that drive Cas9 functionality and orthogonality. In the Technology Development group, he has focused on the development of genome-wide assays to quantify off-target cleavage events as well as the engineering of advanced technologies to increase Cas protein specificity. Additionally, Paul has worked on characterizing and optimizing multiple CRISPR-Cas systems for use as genome editing tools in human primary cells.
Caribou Biosciences is a pioneer in the genome editing field, advancing the development of CRISPR-Cas technologies for use across many application areas. Currently, Caribou is focused on the pre-clinical development of allogeneic immuno-oncology therapies and the targeted engineering of gut microbes for treatment of a broad range of health issues.